Halozyme's Royalty Diversification Has Outgrown Its Dependence on DARZALEX

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Halozyme reports after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Halozyme's post-earnings price behavior shows significant volatility, with an average absolute Day +1 move of 9.09%—well above typical biotech earnings reactions. The most recent quarter (Q2 2026, reported August 6) produced the most dramatic response: the stock surged 20.24% on Day +1 following the strong beat and guidance raise, with an intraday range of 15.51%. This was the largest post-earnings move in the dataset.

Prior quarters showed more moderate reactions. Q1 2026 (May 11) saw a 6.81% Day +1 gain with a 9.55% range. Q4 2025 (February 17) declined -9.01% on Day +1 with an 8.59% range, likely reflecting the disappointing Q4 2025 results. Earlier quarters in 2025 showed smaller moves, generally in the 2-3% range on Day +1.

The pattern suggests the market has become increasingly reactive to Halozyme's results as the royalty growth story has gained momentum. The 9.09% average Day +1 move indicates investors should expect meaningful volatility following this release, particularly if the company delivers another significant beat or guidance raise similar to Q2. The 9.78% average Day +1 range suggests substantial intraday swings are typical regardless of direction.

Part 2.2: Options Market Expected Move

The options market is pricing a 9.40% expected move by the November 20 expiration, which aligns closely with Halozyme's 9.09% average historical Day +1 move. This suggests options traders are appropriately pricing the stock's typical post-earnings volatility based on recent history. Given the 20.24% Day +1 surge following Q2 results, the current expected move may prove conservative if Halozyme delivers another significant beat and guidance raise.

Part 3: What Analysts Are Saying

Analyst sentiment on Halozyme is overwhelmingly bullish. The stock carries 8 Strong Buy ratings and 2 Hold ratings among the 10 analysts covering it, with no Sell ratings. This translates to an average recommendation of 4.60 on the 5-point scale, indicating strong conviction in the buy thesis.

Sentiment has improved over the past month, with the Strong Buy count increasing from 7 to 8 while Holds declined from 3 to 2. This positive shift reflects growing analyst confidence following the company's strong first-half performance and raised guidance.

The consensus price target sits at $104.60, with a range from $79.00 to $130.00. However, this target implies 19.7% downside from the current price of $130.34, creating an unusual situation where the stock is trading well above the average analyst target despite overwhelmingly bullish ratings. The high-end target of $130.00 is essentially at the current price, while the mean target suggests analysts haven't fully caught up to the stock's recent rally.

This disconnect likely reflects the stock's 94.9% year-to-date surge outpacing analyst target revisions. Recent commentary suggests analysts are in the process of raising targets—one source noted analysts "lifted the implied fair value estimate to $130 from $115"—but the consensus hasn't fully reflected the company's accelerating royalty growth trajectory. The upcoming earnings report could prompt further target increases if management delivers another strong quarter and maintains or raises guidance.

Part 4: Technical Picture

Halozyme's technical setup heading into earnings is exceptionally strong. The Barchart Technical Opinion registers a 100% Buy signal, unchanged from last week but improved from 80% Buy a month ago. This maximum bullish reading reflects powerful momentum as the stock has surged through the year.

Timeframe Analysis:

• Short-term (100% Buy): Maximum buy signal indicates extremely strong near-term momentum with no technical resistance
• Medium-term (100% Buy): Sustained bullish signal confirms the intermediate trend remains firmly positive with no signs of consolidation
• Long-term (100% Buy): Maximum long-term buy reading suggests the multi-month uptrend is intact and well-established

Trend Characteristics: The Maximum strength combined with Strongest direction signals indicate Halozyme is in an exceptionally powerful uptrend across all timeframes—a rare technical environment that suggests strong underlying momentum heading into the earnings release.

The moving average structure confirms this bullish posture. The stock is trading above all key moving averages: the 5-day ($130.00), 10-day ($128.67), 20-day ($122.98), 50-day ($114.94), 100-day ($99.77), and 200-day ($84.24). This perfect alignment with all averages sloping upward represents an ideal technical setup.

The technical picture is unambiguously supportive heading into earnings. With the stock trading above all moving averages and showing maximum buy signals across all timeframes, Halozyme has strong technical momentum behind it. The 54.7% gain above the 200-day moving average indicates an extended rally, which could amplify volatility if results disappoint. However, the lack of any nearby resistance levels and the powerful trend structure suggest the path of least resistance remains higher if the company delivers in line with or above expectations. The $122.98 20-day moving average would represent the first meaningful support level in the event of a post-earnings pullback.